Description
PEG-MGF is the PEGylated variant of MGF (Mechano Growth Factor). Through covalent binding of a polyethylene glycol chain to the peptide, the half-life is substantially extended, from a few minutes for native MGF to approximately 48-72 hours in preclinical models. This modification fundamentally changes the research profile: while MGF is a tool for locally limited, acute applications, PEG-MGF enables systemic research setups with longer activity intervals.
The underlying mechanism is identical to MGF: activation of satellite cells, repair cascade in skeletal muscle tissue, action through the E-domain and secondarily through IGF-1 receptors. PEGylation does not change the activity axes, but primarily the pharmacokinetic parameters.
In research setups, the longer half-life of PEG-MGF allows reduced application frequency compared to native MGF, which reduces operational complexity in multi-week studies. However, research application is systemic, not local, which must be considered in study design choice.
PEGylation is an established strategy for half-life extension in peptide research, also used in other compounds (PEG-IFN, PEG-EPO, etc.). Research experience with PEGylated compounds is substantial.
PEG-MGF is available in 2mg vials as 10-vial packs.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
PEG-MGF is considered well tolerated per study reports. The mechanism of action is identical to MGF; PEGylation primarily extends the half-life - which makes research application systemic rather than local.
Observed in research and user reports:
- Injection site: mild redness, pressure or transient irritation at the injection site is the most common observation with subcutaneous use.
- Systemic exposure: due to the long half-life, exposure is systemic and more sustained than with native MGF, which should be considered in study design choice.
- Anabolic pathway activation: because PEG-MGF triggers proliferative repair cascades in studies, the literature discusses a theoretical concern that existing abnormal tissue could also be co-stimulated. No evidence supports this.
- Occasionally brief fatigue or a mild feeling of warmth shortly after application is reported.
- No long-term data: robust long-term human studies do not exist. The profile rests primarily on foundational MGF research and experience with PEGylated compounds.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- PEGylation of peptides: pharmacokinetic effects - Advanced Drug Delivery Reviews 2008: Mechanism of the PEGylation strategy.
- Mechano growth factor in muscle research - Journal of Applied Physiology 2003: MGF fundamentals.
- Long-acting peptide therapeutics - Nature Reviews Drug Discovery 2018: Research context of long-acting peptides.
